Multiple endocrine neoplasia type 2A (MEN2A) is predisposed by mutations in the RET proto-oncogene. Low expression of the cyclin-dependent kinase inhibitor (CDKI) p27
Introduction
Multiple endocrine neoplasia (MEN) is an autosomal dominant cancer syndrome characterized by the concurrent development of adenomatous hyperplasia and multiple malignant endocrine tumors in individual members of affected families. MEN type 2A (MEN2A), a subset of the MEN syndrome characterized by the occurrence of medullary thyroid carcinomas, adrenal medullary pheochromocytomas and parathyroid hyperplasia, is caused by germline-activating missense mutations in the extracellular domain (Mulligan et al., 1993; Kodama et al., 2005) of the RET transmembrane receptor tyrosine kinase (TK). The most common MEN2A-specific RET mutation, RET2A C634R (RET2A; Eng et al., 1996) , results in the formation of an intermolecular disulfide linkage between two RET2A monomers, subsequent ligand-independent dimerization and constitutive activation (Santoro et al., 1995) . Following RET activation, several downstream signaltransduction pathways become activated, including the p42/p44 mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase (PI3K), p38 MAPK and c-Jun N-terminal kinase (JNK) pathways. These pathways are known to play vital roles in mitogenesis and cellular transformation (Kodama et al., 2005) .
During mammalian cell cycle progression, the critical transition from the G1 to S phase is controlled by a family of serine/threonine protein kinases, collectively referred to as cyclin-dependent kinases (CDKs); reviewed by Sherr and Roberts (1999) and Malumbres and Barbacid (2001) . The catalytic activity of a CDK is positively regulated by binding to its activating cyclin subunit. For example, CDK4 activity is positively regulated by binding to D-type cyclins. CDKs are negatively regulated by CDK inhibitors (CDKIs), which are grouped into two families -INK4 and CIP/KIP. p16 Ink4a , p15
Ink4b , p18 Ink4c and p19 Ink4d are INK4 CDKI family members, which bind and specifically inhibit CDK4 or CDK6 by excluding D-type cyclins (Brotherton et al., 1998; Russo et al., 1998) . p21 Cip1 , p27
Kip1 and p57
Kip2
form the CIP/KIP CDKI family, which can bind and inhibit a wide range of cyclin/CDK complexes. Although mice lacking either CDKI p18 or p27 develop gigantism, organomegaly and pituitary tumors (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996; Franklin et al., 1998) , a loss of both CDKIs leads to an accelerated tumor spectrum predominantly in endocrine tissues (Franklin et al., , 2000 . Interestingly, the thyroid C cell adenomas, adrenal pheochromocytomas and parathyroid adenomas observed in p18/p27 double-null mice essentially mimic the tumor spectrum of MEN2A patients. These results provided the first evidence of functional collaboration between CDKIs in a tissue-specific manner, and strongly implicate both p18 and p27 as essential tumor suppressors during MEN2 and endocrine tumorigenesis. Indeed, recent evidence demonstrates decreased expression of both of these CDKIs also during non-MEN2A parathyroid tumorigenesis (Buchwald et al., 2004) .
Therefore, we hypothesize that both p18 and p27 are normally regulated by RET signaling, and that they are inappropriately deregulated by the RET2A mutant. To test this possibility, we generated tetracycline-inducible stable cell lines expressing different RET isoforms, including RET2A. We find that under two different growth arrest conditions, RET2A expression correlates with inappropriately decreased p18/p27 and increased cyclin D1/D2 protein expression. Mechanistically, RET2A affects transcript levels of p18, p27 and cyclin D1, and p27 protein stability. This change in cell cycle profile correlates with increases in CDK activity, retinoblastoma protein (pRb) phosphorylation and proliferative index. Blocking RET2A-MAPK signals with MAPK kinase (MEK) inhibitors re-establishes normal elevated p18/p27 expression and growth arrest, but does not affect the inappropriately elevated levels of D-type cyclins. This implicates involvement of the MAPK pathway in RET2A-mediated p18/p27, but not cyclin D, regulation. Using p18 small interfering RNA (siRNA), we demonstrate that p18 repression is both required and sufficient to increase proliferation. Finally, MEN2A adrenal tumors also show these same altered cell cycle protein expression profiles, underscoring the biological relevance of our studies. We conclude that p18 is a potential downstream target of RET signaling and both p18 and p27 functionally collaborate to maintain growth arrest.
Results

Characterization of cells stably expressing tetracyclineinducible RET, RET2A and TrkBRET
Tetracycline-inducible cell lines were established in NIH3T3 cells to regulate expression of LacZ, wild-type (WT) human RET, the MEN2A-specific constitutively active RET2A C634R mutant and a TrkBRET chimera ( Figure 1a ). The TrkBRET chimera was generated by fusing the RET intracellular TK domain in-frame with the extracellular ligand-binding and transmembrane domains of another receptor TK, TrkA. The TrkBRET chimera was constructed in order to activate the RET TK domain in a coreceptor-independent, but liganddependent manner by using the TrkA ligand, nerve growth factor (NGF; Kaplan et al., 1991) . LacZ and TrkBRET. The indicated cell lines were treated with tetracycline and/or NGF. Protein lysates were isolated and analyzed by immunoblotting using antisera against the indicated proteins. Tubulin was used as a protein loading control. Note that RET and RET2A migrate at B150 kDa, whereas TrkBRET migrates at B99 kDa. Nonetheless, all immunoblots for RET, RET2A and TrkBRET are aligned for figure purposes. (c) RET2A-expressing cells and NGF-treated TrkBRET-expressing cells assume morphology consistent with cellular transformation within 4 days (rounded, refractile cells, bolded panels). This morphology is reversed by removal of tetracycline (in RET2A or TrkBRET cells) or NGF (only in TrkBRET cells). Results for panels b and c are from a minimum of four independent experiments. inactive WT RET serve as negative controls in our experiments.
RET, RET2A and TrkBRET are efficiently expressed in a tetracycline-dependent manner (Figure 1b, . The partial (150 kDa) and completely glycosylated (170 kDa) forms of RET are detected (Takahashi et al., 1991 (Takahashi et al., , 1993 . The TrkBRET chimera is also detected using an anti-TrkA antibody (data not shown). TrkBRET also migrates on SDS-PAGE as two separate bands, suggesting it is glycosylated similar to parental TrkA (Martin-Zanca et al., 1989) . Denoting RET TK activation, RET Y905 phosphorylation is detected in the RET2A, and NGF-treated TrkBRET samples (Figure 1b and Iwashita et al. (1999) and Kawamoto et al. (2004) ). No phosphorylation is seen in control RET cells, despite the presence of NGF, confirming that WT RET is inactive and that NGF is an ineffective RET ligand. Consistent with the literature, expression and/or activation of RET2A or TrkBRET correlates with the phosphorylation of p44/p42 MAPK (Santoro et al., 1994; van Weering et al., 1995; Worby et al., 1996; van Weering and Bos, 1998; Trupp et al., 1999) . MAPK phosphorylation does not occur in the control LacZ or RET cells. Prolonged induction of RET2A (or activated TrkBRET, 4-5 days), results in a rounded and refractile cellular morphology (Figure 1c , bolded panels) that is consistent with RET2A-induced cellular transformation, as previously reported using focus formation assay (Santoro et al., 1994 (Santoro et al., , 1995 Iwashita et al., 1996) . The transformed morphology is completely reversed within 24-48 h of removal of tetracycline and/or NGF from the media. Negative control cells remain non-refractile and flattened, consistent with an untransformed morphology. Combined, these results are consistent with the anticipated biochemical and functional activities of RET (inactive), RET2A (constitutively active) and TrkBRET (liganddependent conditional activation) and are in agreement with previously reported NIH3T3-based RET expression systems.
RET activation correlates with altered expression of G1 cell cycle regulators under conditions of growth arrest The similarity between the tumor spectra of p18/p27 double-null mice (Franklin et al., , 2000 and MEN patients led us to hypothesize that both p18 and p27 are critical tumor suppressors in endocrine tissues and that RET regulates their expression. The adult adrenal and thyroid tissues proliferate, albeit at a very low rate (Tischler et al., 1989; Conde et al., 1992) . As such, one might anticipate that in these endocrine tissues, RET activation would normally promote growth by decreasing p18 and/or p27 expression. Consistent with this notion, oncogenic RET2A activity would lead to aberrantly low levels of p18/p27, even under conditions where they should normally be elevated (i.e. differentiation). This could possibly lead to uncontrolled proliferation, resulting in the formation of MEN2A tumors. To assess whether RET activity correlates with low levels of p18/p27, we grew RET-, RET2A-and TrkBRET-expressing cells under two different growth arrest conditions, serum starvation and confluency contact inhibition. Under such arrested conditions, p18 and p27 protein expression is normally abundant (Polyak et al., 1994; Pagano et al., 1995; Coats et al., 1996; Franklin and Xiong, 1996; Kato et al., 1997) . The rationale was to try to approximate cell culture conditions that best mimic the slow or non-proliferative nature of endocrine tissues, and to permit examination of the full range of mitogenic cell cycle effects by the RET2A mutant under growth arrest conditions.
In an initial serum deprivation experiment, we induced expression of LacZ, RET, RET2A and activated TrkBRET under subconfluent conditions. After 24 h, the cells were subjected to 72 h of serum starvation, while continuing tetracycline/NGF treatments. Consistent with cell cycle arrest by serum starvation, the negative control LacZ and RET cells express high p18 and p27 levels, irrespective of tetracycline treatment ( Figure 2a ). However, RET2A expression leads to an average two-fold reduction in both p18 and p27 protein levels (P ¼ 0.001 and P ¼ 0.002, respectively), as compared to control-uninduced cells. Similar reductions in p18 and p27 protein levels were seen in NGF-treated TrkBRET-expressing cells. Consistent with reports that RET2A can induce cyclin D1 mRNA expression (Schuringa et al., 2001; Watanabe et al., 2002) , RET2A (or activated TrkBRET) expression correlates with a two-fold induction of cyclins D1 (P ¼ 0.006) and D2 (D2 crossreacts with the cyclin D1 antibody), as compared to LacZ and RET and uninduced control cells. Combined, these results indicate that inappropriate activation of RET signaling can decrease p18 and p27 protein expression, whereas elevating cyclins D1 and D2 under conditions of serum deprivation growth arrest.
Such an altered cell cycle expression profile should correlate with a proliferating cell population. To address whether RET activation during serum deprivation growth arrest can indeed lead to inappropriately increased cell cycle progression, we measured proliferative index (total S þ G2/M-phase cells) by flow cytometry (FACS). The proliferative index of induced LacZ cells was set to 1, and the other samples were compared with it to obtain the relative proliferative index (Figure 2b ). In the control LacZ and RET cells, essentially 85-90% of the cells accumulated in G0/G1, irrespective of tetracycline treatment. However, RET2A or activated TrkBRET expression, when induced before serum starvation, results in a 2.5-to three-fold higher proliferative index, approaching 20-30% of the total cell population (P ¼ 0.003 and P ¼ 0.002, respectively). These results correlate very well with the altered cell cycle expression profile resulting from RET activation, and suggest that inappropriate RET activity prevents or delays growth arrest by serum deprivation.
We next assessed whether RET2A expression could enable cells to escape growth arrest after serum starvation was already established. To address this issue, 40% subconfluent RET2A cells were arrested by serum deprivation for 3 days (Figure 2c , 0 h), and then treated in the presence or absence of tetracycline for an additional 24, 48 and 72 h (maintaining serum deprivation). The uninduced RET2A control cells show high p18/p27 levels and low cyclin D1/D2 protein levels, suggesting a profile consistent with proper serum starvation growth arrest. As expected, RET2A expression correlates with induction of cyclins D1/D2. Surprisingly, under these conditions there is no observable decrease in p18/p27 expression in the RET2A-induced cells. FACS analysis of parallel cultures reveals no significant increase in proliferative index in the RET2A-expressing cells, as compared to the uninduced cells (P>0.05 for all time points, data not shown). These cells remain arrested, with 80-90% of the cells in the G0/G1 phase.
Consistent with previous reports, we found that serum starvation in our negative control cells correlates with a high background of MAPK phosphorylation (data not shown and Jung et al. (1999) . Additionally, it takes 3 days of serum starvation for cyclin D1/D2 levels to decrease sufficiently in the control cells. Such prolonged RET2A expression (4 days) results in cells that assume a 'transformed-like' morphology ( Figure 1c) . In order to confirm that RET2A-mediated p18/p27 and cyclin D results were owing to RET signaling and not due to secondary effects of cellular transformation, we carried out experiments under a second growth arrest condition, confluency contact inhibition. Under this condition, MAPK phosphorylation occurs only in response to RET2A or activated TrkBRET (Figure 1b) , and the shortened induction does not result in any morphological changes.
NIH3T3, LacZ, RET, RET2A and TrkBRET cells were grown to 80% confluence and treated with tetracycline and/or NGF. The cells reached 100% confluency 24 h later, and were harvested after an additional 24 h post-confluent incubation. The negative control cells express high levels of p18 and p27 (Figure 3a) . In comparison to uninduced cells, we detected three-fold decreases in p18 and p27 protein levels (P ¼ 0.003 and P ¼ 0.004, respectively), correlate with RET2A or activated TrkBRET expression. Cyclin D1/D2 levels remained low in post-confluent negative control cells. Conversely, there was more than a three-fold increase in D-type cyclin expression (P ¼ 0.0002) correlate with RET2A or activated TrkBRET expression. Finally, we detected a consistent 1.5-fold induction of the CDKI p21 in RET2A or activated TrkBRET-expressing cells.
This altered cell cycle expression profile produced by activated RET cells correlates with resistance to confluency growth arrest (Figure 3b or RET induction (relative proliferative index of induced LacZ cells was set to 1). However, in RET2A or activated TrkBRET-expressing cells, proliferation increases two-to three-fold (P ¼ 0.003 and P ¼ 0.009, respectively), with more than 20% of the total population in the S and G2/M phases. Combined, these results demonstrate that activated RET signaling correlates with a downregulation of p18/p27 expression and an increase in D-type cyclin levels, regardless of the conditions of growth arrest (serum starvation or confluency arrest). This inappropriate cell cycle expression profile allows cells to escape G0/G1 arrest and enter into the S phase, whereas control cells, with normal cell cycle regulation, become efficiently growth arrested. As RET2A failed to decrease p18/p27 levels or increase proliferation if cells were already arrested by serum deprivation before RET2A induction, we examined if this occurs if cells first became postconfluent before RET2A expression. RET2A cells were grown to 100% confluency ( Figure 3c , 0 h), and then induced for RET2A expression for 24, 48 or 72 h. Under these conditions, RET2A expression correlates with elevated cyclin D1/D2 expression within 24 h postconfluency, yet there is no observable decrease in p18/p27 levels even after 72 h ( Figure 3c ). This cell cycle expression profile correlates with accumulation of RET2A-induced G0/G1 growtharrested cells (data not shown).
The combined results from the serum deprivation and confluency experiments allow five important conclusions. First, activated RET signaling can affect G1 cell cycle protein expression, and increase proliferation, but only when RET is initially expressed under subconfluent or proliferative conditions. Second, once growth arrest is established, RET2A signals are unable to mediate a decrease in p18/p27 expression. This is not the case for RET2A-mediated increase in cyclin D, which can be induced in previously growth-arrested RET2A-expressing cells. Third, RET2A-mediated induction of cyclin D alone is insufficient to enhance proliferation. Fourth, an increase in proliferation appears to require RETmediated downregulation of p18/p27. Finally, the results in our confluency studies are obtained before the appearance of any 'transformation-like' morphological changes, suggesting that the observed effects are more likely owing to RET signals, and are not secondary or indirect effects of cellular transformation.
RET-mediated transcriptional regulation of cell cycle proteins To determine mechanistically how RET2A signaling mediates the observed changes in p18, p21, p27 and D-type cyclins, we assessed transcriptional regulation of these loci by quantitative real-time (QRT)-PCR, correlate with RET2A expression under confluency arrest conditions (Figure 4 ). Amplification of ribosomal 18S rRNA was used as a standardization control. Fold change in mRNA in the induced:uninduced LacZ sample was set to 1, and the other samples were compared to LacZ to obtain relative mRNA fold induction/repression. Consistent with protein levels, RET2A expression correlated with a 2.4-fold repression of the shorter p18(S) transcript (P ¼ 0.02), and a 1.5-fold repression in p27 mRNA (P ¼ 0.001). A second and longer p18 mRNA transcript, p18(L), was unaffected by RET2A expression. This is consistent with a previous report that p18(L) transcripts are translationally silent and p18(S) translationally active . p21 mRNA was induced 1.5-fold in RET2A-expressing cells (P ¼ 0.03). Additionally, there was a 6.5-fold induction of cyclin D1 mRNA, correlate with RET2A expression (P ¼ 0.006). This is consistent with a previous study, where RET2A expression correlated with increased cyclin D1 mRNA levels by differential gene display (Watanabe et al., 2002) . In contrast, the RET2A-mediated induction of cyclin D2 protein does not occur via transcriptional mechanisms. To our knowledge, these results show for the first time that RET2A expression correlates with changes in p18 and p21 mRNA transcripts, in addition to the previously reported effects on cyclin D1 and p27 expression (Watanabe et al., 2002; Drosten et al., 2004) .
Stability of p27 protein is decreased in RET2A-expressing cells p27 is regulated at the level of protein stability by the RET/PTC mutant in thyroid follicular carcinoma cells . To address the possibility that RET2A might also decrease p27 protein stability, RET2A cells were grown to 80% confluence and treated for 12 h with tetracycline, after which a sample was processed ( Figure 5a , 0 h). The remaining cells were treated with tetracycline and cycloheximide, and harvested at the indicated time points. RET2A expression is sufficiently induced after 12 h of tetracycline treatment, and is maintained thereafter (Figure 5a ). Irrespective of tetracycline treatment, there was no difference in p27 levels at the 0 h time point. A gradual decrease in p27 expression is observed in uninduced cells, with a p27 half-life of approximately 12 h (Figure 5b ). This prolonged half-life of p27 may be owing to the nearconfluent growth state of the cells, as the half-life of p27 in quiescent cells is 6-8 times longer than that observed in proliferating cells (Pagano et al., 1995) . As expected, the half-life of p27 in RET2A-expressing cells is shortened to about 6-7 h. Surprisingly, the half-life of cyclins D1/D2 is also decreased in RET2A-expressing cells, despite the observed RET2A-mediated increase in D-type cyclin protein expression. Owing to the extended time course used to determine the half-life of p27, we were unable to properly quantitate the half-life of cyclin D1. However, it is interesting to note that we detect a 6.5-fold induction of cyclin D1 transcripts, a decrease in cyclin D1 protein stability, and an overall three-fold increase in cyclin D1 steady-state protein level. In conclusion, these observations indicate that activated RET is able to regulate p27, not only at the mRNA level but also by mediating a more rapid p27 turn over.
RET2A-mediated decrease in p18 and p27 requires functional MAPK signaling
The MAPK pathway has been implicated in regulating cyclin D1, p27 and p21 (Coleman et al., 2004) . We demonstrated that RET2A and activated TrkBRETexpressing cells activate MAPK signaling (Figure 1b) . Therefore, we determined whether MAPK signaling was required to facilitate any of the observed RET2A-mediated cell cycle changes during confluency growth arrest. Cells were grown to 90% confluence and treated for 24 h with tetracycline and/or an MEK inhibitor, PD98059. There was no observable effect on the expression patterns of any of the cell cycle proteins by treating control LacZ-or RET-expressing cells with either tetracycline and/or PD98059 (Figure 6a ). MEK inhibition with PD98059 was confirmed by assessing MAPK phosphorylation (Figure 6b ). Consistently, RET2A expression in the absence of PD98059 correlates with the expected changes in p18, p21, p27 and cyclins D1/D2 expression (Figure 6a) , as compared to controluninduced cells. However, inhibition of MAPK phosphorylation by PD98059 abrogates the RET2A-mediated decrease in p18/p27, and blocks the increase in p21 levels. The induction of cyclins D1/D2 by RET2A remains unaffected. Similar results were obtained using a different MEK inhibitor, UO126 (data not shown). The inability of PD98059 to block cyclin D1 induction is not surprising, as RET2A has been shown to induce cyclin D1 transcription via STAT3 activation (Schuringa et al., 2001) . Combined, these data suggest that whereas the RET2A-mediated induction of cyclins D1/D2 does not require the presence of a functional MAPK pathway, the induction of p21 and the decrease in p18/p27 requires active MAPK signaling.
To further confirm that decreased p18/p27 expression is required to increase proliferation mediated by RET2A, we measured the proliferative index of cells treated with PD98059 (Figure 6c ). When RET2A expression is induced in the absence of PD98059, there is a 1.8-fold increase in proliferation as compared to control-uninduced RET2A cells (P ¼ 0.005), which correlates well with the induction of cyclins D1/D2 and the reduction in p18/p27 (Figure 6a ). However, when RET2A expression is induced in the presence of PD98059, there is only a 1.3-fold increase in proliferation, as compared to the control-uninduced RET2A cells. This proliferative index is statistically different, as compared to RET2A cells grown in the absence of the MEK inhibitor (P ¼ 0.009). This further confirms that RET2A-mediated repression of p18/p27 via MAPK signaling is required to increase proliferation, whereas the induction of D-type cyclins alone is not sufficient.
As p18, p27 and cyclin D1 were all regulated at the level of steady-state mRNA levels, correlating with RET2A expression, we assessed whether this particular mechanism of regulation was mediated via MAPK signaling. Parallel RET2A cultures, grown in the absence or presence of tetracycline and PD98059 under confluency arrest conditions, were analyzed for expression of the various transcripts by QRT-PCR ( Figure 6d ). As expected, RET2A expression correlated with repression of p18(S) and p27 transcripts, and induction of cyclin D1 mRNA (P ¼ 0.001, P ¼ 0.004 and P ¼ 0.003, respectively, as compared to uninduced RET2A cells). However, PD98059 blocked most RET2A-mediated repression of p18(S) and p27 transcripts (P ¼ 0.004 and P ¼ 0.004, respectively, as compared to RET2A-expressing cells in the absence of PD98059). The RET2A-mediated induction of cyclin D1 transcripts remains unaffected by PD98059 (P ¼ 0.35). These results show that the RET2A-mediated p18/p27 reduction is MAPK pathway dependent, whereas cyclin D1 protein induction does not require functional MAPK signaling. an altered cell cycle expression profile (Figures 2a and  3a) and an increase in the proliferative index (Figures 2b  and 3b) . If G0/G1 arrest is already established before RET2A expression, only D-type cyclins are induced, and cells remain arrested (Figures 2c and 3c) . These results indicate that induction of D-type cyclins alone is insufficient to increase proliferation, and that cells also require downregulation of p18 and/or p27.
To determine whether repression of p18 is required or sufficient to increase proliferation, we established RET2A cells that stably express p18 siRNA (RET2A/ p18 siRNA). RET2A and RET2A/p18 siRNA cells were grown to 24 h postconfluency using three different conditions: uninduced for RET2A expression (-Tet), induced for RET2A expression at 80% subconfluency (80% þ Tet), or induced for RET2A expression beginning at 100% confluency (PC þ Tet). All of the cells were harvested at the same 24 h post-confluency time point (Figure 7a cells results in a 60% decrease in p18 protein (Figure 7b) , as compared to control-uninduced RET2A cells. This reduction in p18 protein is even greater than that accomplished by RET2A induction (compare RET2A 80% þ Tet vs any RET2A/p18 siRNA sample). Significantly with low p18 levels, yet maintaining both high D-type cyclins and p27 expression, the RET2A/p18 siRNA PC þ Tet cells possess an increased proliferative index (Figure 7c ), identical to RET2A/p18 siRNA 80% þ Tet cells (P ¼ 0.45), or the RET2A 80% þ Tet cells (P ¼ 0.28). Biochemically, the only difference between RET2A/p18 siRNA ÀTet and RET2A/p18 siRNA PC þ Tet cells is elevation of D-type cyclins (in the PC þ Tet cells). Therefore, in the absence of p18, cyclin D1 induction is now sufficient to increase proliferation. This indicates that low p18 expression is required for elevated cyclin D levels to permit proliferation. The only biochemical difference between RET2A PC þ Tet and RET2A/p18 siRNA PC þ Tet cells is reduced p18 expression (in the RET2A/p18 siRNA PC þ Tet cells), and this is sufficient to increase proliferation. We conclude that p18 reduction is both required and sufficient for RET2A signaling to increase proliferation.
Reduced p18/p27 and high cyclin D1/D2 expression correlates with increased CDK activity and pRb phosphorylation Our previous results suggest that RET2A expression under growth arrest conditions correlates with an altered cell cycle profile that is more consistent with proliferating cells. To further confirm this, we need to address three issues. First, we want to determine the associations of p18, p27 and cyclin D1 in normal CDK complexes of growth-arrested cells. Second, we need to determine the overall activities of these CDK complexes. Finally, we want to address how RET2A expression correlates with changes in the activities of these CDK complexes. Combined, this should verify that the RET2A-mediated changes in p18, p27 and cyclin D1 expression are more consistent with a proliferative profile, and not a growth-arrested profile.
In an initial experiment, we immunodepleted p18, p27 or cyclin D1 from RET2A cells grown under confluent growth arrest conditions (Figure 8a ). Complete depletion of p18 or p27 was confirmed by immunoblotting uninduced RET2A cells. Depletion reduced p18 and p27 expression to essentially undetectable levels, even lower than those seen in the induced RET2A cells. Depletion of p18 resulted in co-depletion of CDK6, indicating that essentially all of CDK6 is normally associated with p18 under these growth arrest conditions. Similarly, CDK4 was significantly reduced, indicating that some, but not all CDK4 is also complexed with p18. Depletion of p27 resulted in significant co-depletion of CDK2, CDK4 and CDK6, indicating that p27 is normally associated in all three complexes during growth arrest conditions. Cyclins D1 and D2 are not expressed in uninduced RET2A cells, but are both highly expressed in RET2A-induced cultures. Therefore, to detect the association of D-type cyclins, we depleted the induced RET2A cells for the D-type cyclins. Depletion of cyclins D1/D2 results in significant co-depletion of both CDK4 and CDK6, indicating that cyclins D1/D2 are complexed with these CDKs in the RET2A-expressing cells.
Combined, these results indicate that in the uninduced growth-arrested cells, the majority of the G1 CDKs are associated with p18 and p27, and are presumably inactive. In addition, with low cyclin D expression, there is little chance for cyclin D1 association in any CDK4 or CDK6 complexes. However, in the induced RET2A cells, with an increase in proliferation, there are low levels of p18/p27, and cyclin D is now in the majority of CDK4 and CDK6 complexes. This should correlate with increased kinase activity. To address how expression of RET2A correlates with CDK activity, we assayed CDK2 and CDK4 activities using histone H1 and glutathione S-transferase (GST)-pRb as substrates in an in vitro assay (Figure 8b ). In uninduced RET2A cells, CDK2 and CDK4 activities are low. Upon RET2A expression, CDK2 and CDK4 activities increase dramatically. We further confirmed the activities of the G1 CDKs by assessing pRb phosphorylation (Figure 8c ). Total pRb expression does not change correlate with RET2A expression, but pRb phosphorylation does increase in the RET2A-expressing cells.
Combined, these results demonstrate how RET2A expression correlates with not only changes in cell cycle expression profile and increased proliferation but also in the make-up of the CDK complexes that shift the balance towards an increase in G1 and G1/S CDK activities and the hyperphosphorylation of pRb. This helps to address how inappropriate RET2A signaling might allow cells to overcome G1 growth arrest and continue to proliferate.
MEN2A tumor samples display similarly altered cell cycle expression profiles
We next attempted to answer two important questions. First, are the RET2A-mediated changes in cell cycle expression and function that we detect in our cell culture system biologically relevant? Second, can we use all of our results to propose a model for how the constitutively active RET2A mutant inappropriately deregulates the cell cycle machinery to allow increased proliferation in what is essentially a growth-arrested cell type? To address these issues, we obtained serial sections of (1 mg) from each sample was immunodepleted using antibodies against p18, p27 or cyclin D1. The undepleted control lysates were processed in the absence of the antibodies. The lysates were analyzed by immunoblotting using antisera against the indicated proteins. Tubulin was used as a protein loading control. (b) The same protein lysates (1 mg) were immunoprecipitated with antibodies against either CDK2 or CDK4. The immunocomplexes were assayed in vitro for kinase activity using either histone H1 or a GST-pRb fusion protein as substrates. (c) The same protein lysates were analyzed by immunoblotting using antisera against pRb and phospho-pRb S780 . The anti-pRb antibody detects both hypophosphorylated (pRb) and hyperphosphorylated (phospho-pRb) pRb species. The phosphopRb S780 antibody only detects the slower migrating phospho-pRb species. Results shown for panel a are representative of four independent experiments, and panels b and c from two independent experiments. normal adrenal and MEN2A pheochromocytoma (adrenal medullary tumor cells expressing the RE-T2A C634R mutation) tissue samples, and immunostained them with antibodies against p18, p27, cyclin D1, CDK2, CDK4 and CDK6 ( Figure 9 and Table 1 ). Both normal adrenal medullary chromaffin cells and MEN2A pheochromocytoma tumor cells express dopamine-bhydroxylase (DBH), a marker expressed selectively in noradrenergic and adrenergic neurons, as well as in neuroendocrine cells, such as those found in the adrenal medulla (Kim et al., 1998) . Consistent with our cell culture results, the MEN2A tumor cells express decreased levels of p18 and p27 and increased levels of cyclin D1, as compared to normal adrenal samples. Interestingly, in the normal adrenal sections, p18, p27 and cyclin D1 were localized almost exclusively in the cytoplasm (the percentage of positively staining nuclei is indicated in upper right corner of each panel and is summarized in Table 1 ). In the MEN2A tumor samples, much of p27 and cyclin D1 are relocalized to the nucleus. CDK2 and CDK4 expression levels do not appear to change between normal and MEN2A samples, but the positive nuclear index increased dramatically in the MEN2A tumors. In addition to the increased nuclear localization, CDK6 expression is also greatly increased in the MEN2A tumors, compared to the normal samples.
Combined, these results demonstrate that our cell culture results do indeed mimic the actual MEN2A patient tumor samples, in that there is a decrease in CDKIs p18 and p27, with a concomitant increase in D-type cyclins. With this altered pattern of cell cycle expression, in conjunction with the changes in nuclear localization in the MEN2A tumor samples, we propose a possible model for how RET2A expression alters the cell cycle machinery to increase MEN2A tumor growth (Figure 10 ). In normal adrenal medullary cells, p18 is expressed in the cytoplasm in complexes with some of CDK4 and essentially all of CDK6. Similarly, p27 is found in the cytoplasm in complexes with CDK2, CDK4 and CDK6. In addition, with low cyclin D expression, and cytoplasmic localization, these early G1 CDK complexes are all maintained in an inactive state. In MEN2A tumor samples, there is a dramatic change in the expression, localization and activity of these complexes. With low p18 and p27 expression, and high cyclin D1 levels, this allows assembly of active CDK4 and CDK6 complexes, and their relocation to the nucleus in the MEN2A tumor samples. We also propose that decreased p27 levels become rate-limiting in CDK2 complexes, which also become active and are now found in the nucleus. Combined, these changes in the cell cycle machinery enable cells to escape growth arrest, re-enter the active cell cycle and permit the inappropriate proliferation that is associated with MEN2A tumor growth.
Discussion
The RET proto-oncogene is known to activate numerous signaling pathways, driving diverse cellular functions.
However, we do not yet have a full appreciation for possible mechanisms by which RET mutants such as RET2A promote MEN tumorigenesis. Mice lacking both p18 and p27 develop a unique multiple endocrine tumor spectrum not manifested in either single knockout animal (Franklin et al., , 2000 , indicating that both p18 and p27 are critical rate-limiting tumor suppressors in endocrine tissues. This spectrum of affected tissue and cell types mimics the human MEN cancer syndrome, leading us to hypothesize that p18 and p27 are potential downstream RET targets, and that the inappropriate activity of the constitutively active RET2A mutant can deregulate the cell cycle to cause MEN tumorigenesis. We undertook this study in order to establish that p18, as well as p27, is inappropriately deregulated by constitutive RET2A signaling, and to show that a simultaneous loss of p18 and p27 is critical for RET2A-mediated growth phenotypes. Consistent with previous literature (van Weering and Bos, 1998), we show that RET2A activates the MAPK signaling pathway and leads to a morphology that is consistent with cellular transformation (Figure 1 ). If RET2A is expressed before establishing growth arrest conditions, cells fail to accumulate p18 and p27 proteins, and maintain abnormally high D-type cyclin levels (Figures 2 and 3 ). This improper cell cycle expression profile correlates with an increased proliferative index under different growth arrest conditions. However, if quiescent G0/G1 arrest is established before RET2A expression, p18 and p27 levels will increase to normal levels and cells will properly arrest, despite high cyclin D levels. By itself, RET2A-mediated increase in D-type cyclin levels is insufficient to promote growth. However, D-type cyclins can increase proliferation in cells if p18 levels are sufficiently reduced, indicating the requirement for a RET2A-dependent repression of p18 to increase proliferation. When taken in context with the requirement for the loss of both p18 and p27 for mice to develop a MEN-like tumor spectrum (Franklin et al., , 2000 , both p18 and p27 appear to be critical to RET2A growth and tumor suppression phenotypes.
Mechanistically, we show that RET2A expression leads to reduced p18/p27 mRNA levels while inducing cyclin D1 mRNA levels, and regulation of CDKI mRNA levels are mediated through RET-MAPK signaling (Figures 4 and 6) . Inhibiting MAPK signals alleviates the repressive effect of RET2A on p18/p27 mRNA levels, thereby increasing p18/p27 protein levels and re-establishing growth arrest. RET2A expression also leads to decreased p27 protein stability ( Figure 5 ). These p27 results are consistent with the literature, as sustained MAPK activation can downregulate p27 by decreasing its synthesis and accelerating its degradation (Kawada et al., 1997; Weber et al., 1997; Greulich and Erikson, 1998; Chiariello et al., 2000) . Importantly, we believe this is the first example for p18 transcriptional regulation via the MAPK pathway, demonstrating mechanistically how p18 is regulated by RET signaling. Similar p27 and cyclin D1 results were reported using constitutively active RET/PTC1-expressing cells . The mutant RET/PTC1 is associated with the incidence of papillary thyroid carcinoma in thyroid follicular cells (Sozzi et al., 1991; Tong et al., 1995; Celetti et al., 2004) . Expression of RET/PTC1 results in decreased p27 protein levels and increased proliferation. RET/PTC1-mediated p27 regulation was MAPK-dependent. Treatment of RET/ PTC1 cells with RET inhibitors, PP1 or ZD6474, leads to G0/G1 cell cycle arrest, with a correlate increase in p27 and decrease in cyclins D1 and E protein levels. However, blocking this p27 increase with p27 siRNA only partially rescued the RET/PTC1 proliferation phenotype . We suggest that repression of p27 is required for at least a portion of the observed increase in proliferation, and that some other inhibitor may also function to mediate the partial growth arrest observed in their experiment. We propose that in the RET/PTC1 p27 siRNA experiment, p18 accumulates in ZD6474-treated RET/ PTC1 cells. If this is so, even with reduced p27 expression using p27 siRNAs, it is possible that p18 accumulation could sufficiently establish partial growth arrest, as reported. As the status of p18 was not indicated in that study, this possibility cannot be ruled out. In our study, blocking the increase in p18 protein with p18 siRNAs completely rescued the proliferation phenotype ( Figure 7) . We propose that in this p18 siRNA experiment, the reduction of p18 expression not only abrogates p18 function but also creates more G1 CDK complexes with which p27 must associate. This would effectively lessen the ability of p27 to inactivate not only CDK4 or CDK6 but also CDK2 complexes. This p27 titration results in p27 becoming as ratelimiting as p18, so that no specific G1 or G1/S checkpoint becomes fully inhibited (Figure 8 ). This would completely prevent growth arrest and rescue the proliferation phenotype. Such a titration would not be possible in the RET/PTC1 study, as p18 cannot bind to, or inhibit E-type CDK2 complexes. Therefore, p18 levels still maintain the inactivation of CDK4 and CDK6, resulting in the observed partial rescue phenotype. Regardless, results from both studies further support the collaborative nature of p18 and p27 in endocrine tumor suppression.
This hypothesis is further supported by our immunodepletion studies in that, in growth-arrested uninduced RET2A cells, p18 binds to and inhibits essentially all of CDK6 and some CDK4, whereas p27 is found in complexes with CDK2, CDK4 and CDK6 (Figure 8 ). RET2A expression leads to decreased levels of p18 and p27 in conjunction with increased D-type cyclin expression, the increased association of cyclins D1/D2 in CDK4 and CDK6 complexes, and eventually to activation of G1 and G1/S CDK complexes. Most importantly, these results are confirmed in MEN2A adrenal tumor samples that express the RET2A mutant ( Figure 9 ). These tumor cells express low p18 and p27, and high cyclin D1 levels, as compared with normal adrenal tissue. There is also a dramatic increase in CDK6 levels in the MEN2A tumors. Significantly, we also detected a shift of cell cycle proteins from the cytoplasm in normal adrenal tissues, to the nucleus in the MEN2A tumor cells. This correlates with increase in CDK activity, which should enable the inappropriate cell cycle progression associated with MEN2A tumorigenesis. It should also be noted that in two additional endocrine tumor cell lines, p18 expression is affected. In the TT human medullary thyroid carcinoma cell line, the p18 locus is deleted (Acton et al., 2004) , and in rat PC12 pheochromocytoma cells, we are unable to detect p18 expression under any growth conditions (data not shown). These results from other endocrine cell lines may reflect the overall need to somehow downregulate p18 expression, be it by deletion or epigenetic events, as a requisite for endocrine tumor formation. Regardless, the results from the MEN2A tumors, as well as from these other endocrine cell lines, help to confirm the biological relevance of our cell culture-based experiments and to establish not only p27 but also p18 as a critical tumor suppressor in endocrine cells.
Materials and methods
Plasmids and cell culture Human RET51 and RET2A C634R [also in RET51, kindly provided by C Eng; Marsh et al., (1997) ], were subcloned into the mammalian Tet-On expression vector pcDNA4 (Invitrogen, CA, USA). pcDNA3-TrkA has been described previously (kindly provided by P Perez; Perez et al. (1995) ). The TrkBRET chimera was generated by subcloning a PCR fragment (amino acid (a.a.) 1-506) of rat TrkA, amplified using a T7 5 0 forward primer (5 0 -TAATACGACTCACTA TAGGG-3 0 ) and a 3 0 reverse primer (5 0 -GGGAATTCGTG GACACAGGTATCACTGAAGTAC-3 0 ) containing an inframe EcoR1 site for subcloning purposes, in-frame with (a.a. 718-1114) RET (Figure 1a 1 C hold. The insert was verified on both strands by DNA sequencing. Vector-based short hairpin p18 siRNA plasmids were created by inserting three different oligonucleotides (5 0 -GAGTTCCT TATGAAGCACACA-3 0 , 5 0 -ATGAAACTTGGAAATCCG GAG-3 0 and 5 0 -ATGTAAACGTCAACGCTCAAA-3 0 ), complimentary to the mouse p18 mRNA (Accession no. BC027026), into the expression vector pRNA-U6.1/Neo (SD1201) (GeneScript, Scotch Plains, NJ, USA).
NIH3T3 fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 500 U/ml penicillin-500 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) and incubated at 371C and 5% CO 2 . Transfection was carried out using Polyfect transfection reagent according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). Stable foci carrying pcDNA6-TR, a Tet repressor expression plasmid, were selected and amplified in medium containing 12 mg/ml blasticidin (Invitrogen, CA, USA) for 2 weeks. Resulting foci were transiently transfected with a pcDNA4-LacZ control plasmid and assayed for tight repression or high inducibility in the absence or presence of tetracycline, respectively. Ethanol was always added as a negative vehicle control (ÀTet) for all experiments. A second transfection of the pcDNA6-TR foci with pcDNA4 vectors carrying cDNA for LacZ, RET, RET2A or TrkBRET was performed followed by selection in medium containing 12 mg/ml blasticidin and 1000 mg/ml zeocin (Invitrogen, CA, USA). Resulting foci were screened by Western blot following 24 h of induction with 2 mg/ml tetracycline (Sigma, St Louis, MO, USA). Five independent RET clones, five independent RET2A clones and seven independent TrkBRET clones were selected for further characterization. Only one clone of each is shown in our results, but all clones of a given RET isoform produced similar results. Three independent RET2A clones that stably express p18 siRNA (RET2A/p18 siRNA) were selected in medium containing 500 mg/ml G418. Expressed TrkBRET was activated by the addition of its ligand, NGF. Again, only one RET2A/p18 siRNA clone is shown in our results, but all three clones produced similar results. Cycloheximide (10 mg/ ml) was purchased from Sigma, (MO, USA). MEK inhibitors PD98059 (100 mM) and UO126 (10 mM), and human recombinant NGF (50 mg/ml) were purchased from Calbiochem, San Diego, CA, USA. Phase-contrast micrographs were visualized using an Olympus XL-71 inverted microscope, DP-70 digital camera and associated DP-70 software at Â 600 total magnification.
Antibodies
For immunoblotting, commercially purchased primary antibodies include: goat anti-RET (C-20), mouse anti-p27 (F-8), rabbit anti-p44/42 MAPK (C-16), rabbit anti-phosphop44/42 MAPK antisera, and rabbit anti-phospho-Rb S780 antisera (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-tubulin (Ab-4, NeoMarkers, Fremont, CA, USA), rabbit anti-phospho-RET Y905 and rabbit anti-TrkA antibody (Upstate Cell Signaling, Beverly, MA, USA), and anti-Rb (Pharmingen, San Diego, CA, USA). Rabbit primary polyclonal antisera against mouse RET (03-20) and mouse p27 (03-22) were also generated from C terminal peptide epitopescVSPSAAKLMDTFDS (residues 1102-1115 for mouse RET) and cVEQTPKKPGLRRQT (residues 184-197 for mouse p27). KLH-coupled peptides were used to immunize rabbits (Purdue University Biology Department Antibody Production Service). The specificity of newly generated antibodies was characterized by Western blot for the ability to detect RET or p27, respectively. Both reagents were found to react equally, if not better than the comparable commercial source antisera (data not shown). The p27 polyclonal reagent did not crossreact with other CIP/KIP proteins. Other anti-cyclin D1, anti-p21 and anti-p18 rabbit polyclonal antibodies for immunoblotting have been described previously (Franklin and Xiong, 1996; Phelps and Xiong, 1998) . For immunostaining human adrenal sections, commercially purchased primary antibodies (all from Santa Cruz, CA, USA) include: mouse anti-p18 (118.2, 4 mg/ml), rabbit anti-p27 (C-19, 2 mg/ml), rabbit anti-cyclin D1 (H-295, 2 mg/ml), goat anti-CDK2 (M-2, 2 mg/ml), goat anti-CDK4 (C-22, 2 mg/ml), goat anti-CDK6 (C-21, 2 mg/ml) and rabbit anti-DBH (H-213, 2 mg/ml). Secondary antibodies include peroxidase-conjugated goat anti-mouse immunoglobulin IgG (Caltag, Burlingame, CA, USA) and peroxidase-conjugated goat anti-rabbit or donkey anti-goat IgG (Jackson ImmunoResearch Labs, West Grove, PA, USA), IR Dye 800-conjugated goat anti-rabbit or anti-mouse IgG (Rockland Immunochemicals, Gilbertsville, PA, USA), Alexa Fluor 680 conjugated goat anti-rabbit or anti-mouse IgG or donkey anti-goat IgG (Molecular Probes, Eugene, OR, USA).
Immunoblotting, immunodepletions and immunoprecipitationkinase assays All procedures for immunoblotting, immunodepletions and kinase assays have been reported previously (Jenkins and Xiong, 1995; Franklin and Xiong, 1996) . Protein lysates were quantitated and standardized using Bradford assay. All quantitations for immunoblotting, immunodepletions or kinase assays were performed using UN-SCAN-IT gel version 5.1 or Licor Odyssey v1.2. Individual lanes were normalized to tubulin and fold change was calculated as the ratio of induced ( þ Tet) to uninduced (ÀTet) values (unless indicated otherwise in figure legends). The average relative fold change in band intensities were compared to a negative control (standardized to 1, as indicated in figure legends). The Student's t-test was performed to obtain the indicated P-values. For immunodepletions, 1 mg lysate was added to antibody-bound protein A beads and incubated for 1 h at 41C and then pelleted. Depleted lysate was then incubated with a fresh aliquot of antibodybound beads. This process was carried out thrice and the depleted lysate was removed. Equal amount of loading dye was added to the lysates and 150 mg protein was loaded on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, followed by immunoblotting. For immunoprecipitation (IP)-kinase assay, 1 mg lysate was immunoprecipitated with the indicated bead-bound antibodies for 4 h at 41C with rotation. The bead-bound antibodies were washed twice with 1 ml lysis buffer and once with kinase buffer (50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethane sulfonic acid, pH 7.0, 10 mM MgCl 2 , 5 mM MnCl 2 , 1 mM dithiothreitol (DTT), and 5 mM ATP) on ice. Master mix containing substrate (8 mg H1 for CDK2, 4 mg GST-pRb for CDK4), kinase buffer and 5 mCi [g-32 P]ATP was added to the IP beads and incubated at 301C for 30 min. The kinase reaction was stopped by adding protein loading dye and heating at 1001C for 4 min. The kinase reactions were resolved on a 15% SDS-PAGE gel. The gel was stained with Coomassie Blue, destained, dried on a gel-dryer and exposed to X-ray film.
Immunohistochemistry
Serial tissue sections of four normal human adrenal tissues and three MEN2A adrenal medullary pheochromocytoma tumor samples were obtained from the Department of Pathology/ University Medical Center Utrecht-Biobank, (Utrecht, The Netherlands). Slides were stained with hematoxylin and eosin (H&E) or immunostained using the Vectastain ABC Elite immunostaining kit (Vector Laboratory), according to the manufacturer's suggested protocol. Slides for immunostaining were rehydrated in decreasing ethanol concentrations, incubated in 10 mM sodium citrate buffer, pH 6.0, with 0.01% (w/v) ethylenediaminetetra acetic acid for antigen retrieval, incubated in 3% H 2 O 2 and blocked in either horse or goat serum (depending on the host species for the primary antibody, see above Antibody section). Samples were incubated with primary and biotinylated secondary antibodies, then treated with the Vectastain Elite ABC reagent, followed by incubation with the diaminobenzidine substrate. Samples were then counterstained with 1 Â Gills hematoxylin solution, and dehydrated in increasing ethanol concentrations. Phase contrast micrographs were visualized using an Olympus XL-71 inverted microscope, DP-70 digital camera and associated DP-70 software at Â 600 total magnification. Positive staining of nuclei was quantitated from a minimum of at least 350 nuclei per tissue sample.
RNA isolation, reverse transcription and QRT-PCR Total RNA was isolated using TRI Reagent (Sigma) followed by chloroform extraction and isopropanol precipitation. Equal amounts of RNA were digested with RQ1 DNAse (Promega, Madison, WI, USA) and precipitated with 100% ethanol. cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen, CA, USA) in the presence of 1 mg random hexamers (Integrated DNA Technologies, Coralville, IA, USA), 1 mM deoxynucleoside triphosphate (Integrated DNA Technologies, Carolville, IA, USA) and 200 mM DTT.
Equal amounts of cDNA and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) were used in each reaction of QRT-PCR in the ABI prism 7000 sequence detection system (Applied Biosystems, CA, USA). The QRT-PCR parameters were: 501C/2 min -one cycle; 951C/ 10 min -one cycle and 951C/15 s, 60 o C/1 min -40 cycles. Data were analyzed, according to the manufacturer's recommendations, to obtain fold induction or repression of target gene transcripts relative to 18S rRNA, and subjected to statistical analysis using Student's t-test. The primer sequences for each target gene, designed using Primer Express software provided by Applied Biosystem's, are as follows:
18S rRNA forward primer (5 0 -CACGGCCGGTACAGTG AAA-3 0 ), 18S rRNA reverse primer (5 0 -AGAGGAGCGAGCGACC AA-3 0 ); p18(S) CDKI forward primer (5 0 -ACCATCCCAGTCCTT CTGTCA-3 0 ), p18(S) CDKI reverse primer (5 0 -GTTGCTTCACTTT TTCCCCTTTC-3 0 ); p18(L) CDKI forward primer (5 0 -AGCGAGCAGCACTCT GGACTA-3 0 ), p18(L) CDKI reverse primer (5 0 -GCAGAATTTCAGAGT CAGGTCCTT-3 0 ); p27 CDKI forward primer (5 0 -CTTCCGCCTGCAGAAAT CTCT-3 0 ), p27 CDKI reverse primer (5 0 -CGGCAGTGCTTCTCCA AGTC-3 0 ); p21 CDKI forward primer (5 0 -GCAGATCCACAGCGAT ATCCA-3 0 ), p21 CDKI reverse primer (5 0 -GAACAGGTCGGACATCA CCTGGATTGG-3 0 ); cyclin D1 forward primer (5 0 -CGTGGCCTCTAAGATGA AGGA-3 0 ), cyclin D1 reverse primer (5 0 -TCGGGCCGGATAgA GTTGT-3 0 ); and cyclin D2 forward primer (5 0 -GCGGGATGTTGACCTGT GA-3 0 ), and cyclin D2 reverse primer (5 0 -GGGCTAGCAGATGAC GAACAC-3 0 ).
Flow cytometry DNA content was analyzed for cell cycle kinetics by FACS. A minimum of three independent experiments were analyzed. Parallel cultures for FACS and immunoblotting were prepared to ascertain consistent results. Cells were harvested and fixed as described previously (Juan and Darzynkiewicz, 1998) . Fixed cells were rinsed in filter-sterilized phosphate-buffered saline and centrifuged. The cell pellet was treated with 100 mg/ml RNAse for 5 min, followed by 50 mg/ml propidium iodide for 30 min in the dark. 675 nm emission from the propidium iodide stained DNA was measured with a Coulter FC-500 flow cytometer. Approximately 30 000 cells were analyzed for each sample with a flow rate of 300-400 cells per second. The percentages of cells within the G1,S and G2/M phases of the cell cycle were determined using the computer program ModFit. The proliferative index was first calculated by obtaining the sum of all S and G2/M-phase populations in any given sample. Then, the ratio of the induced ( þ Tet) to uninduced (ÀTet) samples were calculated for a given sample. The ratio obtained from a designated control sample was set to 1 (see figure legends) . The proliferative indices of the other samples were compared relative to this control sample. Student's t-test was performed to obtain the indicated P-values.
